Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 1/20 | 0.41 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.41 |
| ▸ | ITGAL | P20701 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | CRHBP | P24387 | 2/20 | 0.37 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21462 | 0.91 | ITGB2 (0.50) | ITGB2ICAM1ITGALLMNACRHBP | |
| SCHEMBL4573750 | 0.86 | LMNA (0.56) | ITGB2ICAM1ITGALLMNACRHBP | |
| SCHEMBL4574231 | 0.86 | LMNA (0.56) | ITGB2ICAM1ITGALLMNACRHBP | |
| SCHEMBL4894 | 0.78 | — | — | |
| SCHEMBL1230573 | 0.73 | TSHR (0.36) | — | |
| SCHEMBL130778 | 0.73 | ITGB2 (0.39) | ITGB2ICAM1ITGALLMNACRHBP | |
| SCHEMBL1897286 | 0.72 | TSHR (0.39) | — | |
| SCHEMBL9351 | 0.71 | ITGB2 (0.77) | ITGB2ICAM1ITGALLMNACRHBP | |
| SCHEMBL29408297 | 0.71 | ITGB2 (0.77) | ITGB2ICAM1ITGALLMNACRHBP | |
| SCHEMBL8023323 | 0.71 | ITGB2 (0.77) | ITGB2ICAM1ITGALLMNACRHBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 199 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10294246-B2 | Substituted boronic acids and boronate esters as immunoproteasome inhibitors | MERCK PATENT GMBH (DE) | 2019-05-21 | — | — | US | claimed |
| EP-2970258-B1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE DEUTSCHLAND (DE) | 2018-04-18 | — | — | EP | claimed |
| US-9657034-B2 | Substituted furo[3,2-c]pyridines, thieno[3,2-c]pyridines, thieno[2,3-d]pyridazines and pyrido[3,4-d]pyridazines as phosphodiesterase type 10A inhibitors | AbbVie Deuschland GmbH & Co. KG (DE) | 2017-05-23 | — | — | US | claimed |
| EP-2776418-B1 | INHIBITORS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE DEUTSCHLAND (DE) | 2017-01-04 | — | — | EP | claimed |
| US-9475808-B2 | Inhibitor compounds of phosphodiesterase type 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-10-25 | — | — | US | claimed |
| US-20160137668-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-05-19 | — | — | US | claimed |
| US-9273068-B2 | Substituted isoquinolines and phthalazines as inhibitors of phosphodiesterase type 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-03-01 | — | — | US | claimed |
| EP-2970258-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co KG (DE) | 2016-01-20 | — | — | EP | claimed |
| US-20160002231-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE INC. | 2016-01-07 | — | — | US | claimed |
| US-9200005-B2 | Inhibitor compounds of phosphodiesterase type 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-12-01 | — | — | US | claimed |
| US-20100274005-A1 | BICYCLIC PYRAZOLE COMPOUNDS AS ANTIBACTERIAL AGENTS | ALLISON BRETT D | 2010-10-28 | — | — | US | claimed |
| US-20100274004-A1 | BICYCLIC PIRAZOLE COMPOUNDS AS ANTIBACTERIAL AGENTS | ALLISON BRETT D | 2010-10-28 | — | — | US | claimed |
| US-20100227846-A1 | SUBSTITUTED PYRAZOLE DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-09 | — | — | US | claimed |
| EP-2194045-A1 | SUBSTITUTED PYRAZOLE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2010-06-09 | — | — | EP | claimed |
| US-20100087434-A1 | NK-1 and Serotonin Transporter Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-08 | — | — | US | claimed |
| US-20090270359-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | claimed |
| EP-1863483-A1 | BICYCLIC PYRAZOLE COMPOUNDS AS ANTIBACTERIAL AGENTS | Janssen Pharmaceutica, N.V. (BE) | 2007-12-12 | — | — | EP | claimed |
| US-20070249607-A1 | NK-1 AND SEROTONIN TRANSPORTER INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-25 | — | — | US | claimed |
| US-20060223810-A1 | Bicyclic pyrazole compounds as antibacterial agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-10-05 | — | — | US | claimed |
| WO-2006105289-A1 | BICYCLIC PYRAZOLE COMPOUNDS AS ANTIBACTERIAL AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-10-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100274005-A1 | BICYCLIC PYRAZOLE COMPOUNDS AS ANTIBACTERIAL AGENTS | NOD2, BAK1, CASP3 | ITGB2 4267/4885ICAM1 3763/4885ITGAL 4559/4885 |
| US-20100227846-A1 | SUBSTITUTED PYRAZOLE DERIVATIVE | AR, NR5A1, NR3C2 | ITGB2 2688/4885ICAM1 4321/4885ITGAL 3360/4885 |
| US-20160137668-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE5A, PDE3A, PDE3B | ITGB2 4660/4885ICAM1 2951/4885ITGAL 4481/4885 |
| US-20060223810-A1 | Bicyclic pyrazole compounds as antibacterial agents | NOD2, BAK1, CASP3 | ITGB2 4267/4885ICAM1 3763/4885ITGAL 4559/4885 |
| US-20100274004-A1 | BICYCLIC PIRAZOLE COMPOUNDS AS ANTIBACTERIAL AGENTS | PIR, BAK1, TMBIM6 | ITGB2 2379/4885ICAM1 2928/4885ITGAL 3305/4885 |
| US-10294246-B2 | Substituted boronic acids and boronate esters as immunoproteasome inhibitors | PSMB7, PSMA7, PSMB11 | ITGB2 4741/4885ICAM1 3896/4885ITGAL 4403/4885 |
| US-20160002231-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE5A, PDE3A, PDE2A | ITGB2 4349/4885ICAM1 3885/4885ITGAL 3689/4885 |
| US-20100087434-A1 | NK-1 and Serotonin Transporter Inhibitors | SLC6A4, TPH1, SLC6A2 | ITGB2 3263/4885ICAM1 441/4885ITGAL 2281/4885 |
| US-20090270359-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES | AR, NR5A1, NR3C2 | ITGB2 2653/4885ICAM1 4291/4885ITGAL 3326/4885 |
| US-20070249607-A1 | NK-1 AND SEROTONIN TRANSPORTER INHIBITORS | SLC6A4, TPH1, SLC6A2 | ITGB2 3263/4885ICAM1 441/4885ITGAL 2281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.